Welcome to our dedicated page for CVIB news (Ticker: CVIB), a resource for investors and traders seeking the latest updates and insights on CVIB stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CVIB's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CVIB's position in the market.
Civista Bancshares (NASDAQ:CIVB) reported Q1 2026 net income of $15.0 million, or $0.72 per diluted share, reflecting a 47% increase year‑over‑year and a 22% sequential rise. Results include the November 7, 2025 FSB merger and ~$0.4 million of non‑recurring acquisition adjustments (~$0.02 per share).
Key operating metrics: net interest income $37.8 million (+15.4% YoY), net interest margin 3.85% (up 34 bps YoY), cost of deposits 181 bps, efficiency ratio 60.1%, ROA 1.41%, tangible book value per share $19.70, and a declared quarterly dividend of $0.18 per share.